ES2791524T3 - Fenilacetato de L-ornitina y métodos de elaboración del mismo - Google Patents
Fenilacetato de L-ornitina y métodos de elaboración del mismo Download PDFInfo
- Publication number
- ES2791524T3 ES2791524T3 ES17185173T ES17185173T ES2791524T3 ES 2791524 T3 ES2791524 T3 ES 2791524T3 ES 17185173 T ES17185173 T ES 17185173T ES 17185173 T ES17185173 T ES 17185173T ES 2791524 T3 ES2791524 T3 ES 2791524T3
- Authority
- ES
- Spain
- Prior art keywords
- ornithine
- composition
- phenylacetate
- salt
- ornithine phenylacetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *CCC[C@](C(O)=O)N Chemical compound *CCC[C@](C(O)=O)N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N NCCC[C@@H](C(O)=O)N Chemical compound NCCC[C@@H](C(O)=O)N AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N OC(c1ccccc1)=O Chemical compound OC(c1ccccc1)=O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/32—Phenylacetic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
- C07C227/42—Crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16667609P | 2009-04-03 | 2009-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2791524T3 true ES2791524T3 (es) | 2020-11-04 |
Family
ID=42828717
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20161306T Active ES2928586T3 (es) | 2009-04-03 | 2010-04-01 | Fenilacetato de L-ornitina y métodos para elaborar el mismo |
| ES10759442.6T Active ES2652187T3 (es) | 2009-04-03 | 2010-04-01 | Fenilacetato de l-ornitina y métodos para elaborar el mismo |
| ES17185173T Active ES2791524T3 (es) | 2009-04-03 | 2010-04-01 | Fenilacetato de L-ornitina y métodos de elaboración del mismo |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20161306T Active ES2928586T3 (es) | 2009-04-03 | 2010-04-01 | Fenilacetato de L-ornitina y métodos para elaborar el mismo |
| ES10759442.6T Active ES2652187T3 (es) | 2009-04-03 | 2010-04-01 | Fenilacetato de l-ornitina y métodos para elaborar el mismo |
Country Status (26)
| Country | Link |
|---|---|
| US (9) | US8173706B2 (enExample) |
| EP (4) | EP3686183B1 (enExample) |
| JP (6) | JP6144488B2 (enExample) |
| KR (6) | KR102217081B1 (enExample) |
| CN (3) | CN104230730B (enExample) |
| AU (1) | AU2010232521B2 (enExample) |
| BR (1) | BRPI1013657A2 (enExample) |
| CA (5) | CA2757373C (enExample) |
| CY (1) | CY1119843T1 (enExample) |
| DK (3) | DK2413924T3 (enExample) |
| EA (2) | EA023051B1 (enExample) |
| ES (3) | ES2928586T3 (enExample) |
| HR (2) | HRP20221232T8 (enExample) |
| HU (2) | HUE060371T2 (enExample) |
| IL (2) | IL215449B (enExample) |
| LT (2) | LT2413924T (enExample) |
| MX (4) | MX2011010262A (enExample) |
| NO (1) | NO2413924T3 (enExample) |
| NZ (3) | NZ619235A (enExample) |
| PL (2) | PL2413924T3 (enExample) |
| PT (2) | PT3686183T (enExample) |
| SG (3) | SG10202010988WA (enExample) |
| SI (1) | SI2413924T1 (enExample) |
| SM (2) | SMT201700601T1 (enExample) |
| WO (1) | WO2010115055A1 (enExample) |
| ZA (1) | ZA201107189B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006056794A1 (en) | 2004-11-26 | 2006-06-01 | Ucl Business Plc | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
| SMT201700601T1 (it) | 2009-04-03 | 2018-03-08 | Ocera Therapeutics Inc | L-ornitina fenilacetato e metodi per la sua fabbricazione |
| EP2799067B1 (en) | 2009-06-08 | 2019-04-03 | UCL Business PLC | Treatment of brain inflammation using L-Ornithine Phenylacetate |
| US8068011B1 (en) | 2010-08-27 | 2011-11-29 | Q Street, LLC | System and method for interactive user-directed interfacing between handheld devices and RFID media |
| NZ609191A (en) * | 2010-10-06 | 2015-06-26 | Ocera Therapeutics Inc | Methods of making l-ornithine phenyl acetate |
| CN102993037B (zh) * | 2012-11-20 | 2015-03-04 | 南京工业大学 | 一种l-鸟氨酸苯乙酸盐的制备方法 |
| CN105481725B (zh) * | 2014-09-18 | 2019-01-22 | 博瑞生物医药（苏州）股份有限公司 | L-精氨酸苯乙酸盐的晶型及其制备方法 |
| KR20230018526A (ko) | 2014-11-24 | 2023-02-07 | 유씨엘 비즈니스 리미티드 | 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료 |
| KR20180006904A (ko) * | 2015-04-20 | 2018-01-19 | 오세라 테라퓨틱스, 아이엔씨. | L-오르니틴 페닐아세테이트의 제형 |
| HK1249434A1 (zh) | 2015-08-18 | 2018-11-02 | Ocera Therapeutics, Inc. | 使用与苯乙酸盐和苯丁酸盐中的至少一种组合的l-鸟氨酸治疗和预防肌肉损失 |
| WO2017053613A1 (en) * | 2015-09-25 | 2017-03-30 | Ocera Therapeutics, Inc. | Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
| CA3004331A1 (en) | 2015-11-13 | 2017-05-18 | Ocera Therapeutics, Inc. | Formulations of l-ornithine phenylacetate |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| IL270413B (en) * | 2017-05-11 | 2022-08-01 | Ocera Therapeutics Inc | Processes of making l-ornithine phenylacetate |
| BR112020002419A2 (pt) | 2017-08-14 | 2020-07-28 | Axcella Health Inc. | aminoácido para o tratamento de doença do fígado |
| CN112839643A (zh) | 2018-06-20 | 2021-05-25 | 胺细拉健康公司 | 用于治疗肌肉中脂肪浸润的组合物及方法 |
| JP2022533569A (ja) | 2019-05-09 | 2022-07-25 | オセラ セラピューティクス， インコーポレイテッド | 肝性脳症を評価および処置する方法 |
| CN110707221B (zh) * | 2019-09-25 | 2023-09-01 | 北京大学深圳研究生院 | 氨基酸离子液体在制备钙钛矿光电器件中钙钛矿层的应用 |
| EP4045028A4 (en) * | 2019-10-16 | 2023-11-08 | Ocera Therapeutics, Inc. | DOSAGE AND USES OF ORNITHINE PHENYLACETATE FOR THE TREATMENT OF HYPERAMMONEMIA |
| WO2023240081A1 (en) * | 2022-06-06 | 2023-12-14 | Yale University | Treatment, amelioration, and/or prevention of inflammatory and autoimmune diseases |
| WO2024261477A1 (en) | 2023-06-20 | 2024-12-26 | Yaqrit Limited | Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB965637A (en) | 1962-04-23 | 1964-08-06 | Tanabe Seiyaku Co | L-ornithine l-aspartate |
| NL302572A (enExample) | 1962-12-27 | |||
| GB1067742A (en) | 1963-09-16 | 1967-05-03 | Kyowa Hakko Kogyo Kk | Process for the preparation of l-ornithine l-aspartate |
| ZA716628B (en) | 1970-10-15 | 1972-06-28 | Richardson Merrell Spa | Composition and method for treatment of hepatic disease and mental fatigue |
| FR2113774A1 (en) | 1970-11-13 | 1972-06-30 | Roques Ets | Prepn of l-ornithine salts with org acids - using silver oxides |
| US4100161A (en) | 1974-04-15 | 1978-07-11 | The Johns Hopkins University | Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids |
| US3950529A (en) | 1975-02-03 | 1976-04-13 | Massachusetts General Hospital | Amino acid formulations for patients with liver disease and method of using same |
| US4228099A (en) | 1978-03-17 | 1980-10-14 | The Johns Hopkins University | Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders |
| US4320146A (en) | 1978-03-17 | 1982-03-16 | The Johns Hopkins University | Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids |
| US4352814A (en) | 1979-04-18 | 1982-10-05 | The Johns Hopkins University | Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs |
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US5139981A (en) | 1987-06-24 | 1992-08-18 | Union Carbide Chemicals & Plastics Technology Corporation | Process for preparing silver(I)-exchanged resins |
| JP2522034B2 (ja) * | 1988-12-27 | 1996-08-07 | 味の素株式会社 | α−ケト酸・アミノ酸塩化合物及びその製造方法 |
| JPH03273578A (ja) | 1990-03-23 | 1991-12-04 | Ricoh Co Ltd | 対物レンズクリーニング装置 |
| DE4020980C1 (enExample) | 1990-07-02 | 1991-09-26 | Degussa Ag, 6000 Frankfurt, De | |
| US5591613A (en) | 1990-07-02 | 1997-01-07 | Degussa Aktiengesellschaft | Method for the preparation of D-arginine and L-ornithine |
| JP3127484B2 (ja) | 1991-02-28 | 2001-01-22 | 味の素株式会社 | 肝炎治療薬 |
| US5767086A (en) | 1992-04-03 | 1998-06-16 | Terrapin Technologies, Inc. | Bone marrow stimulation by certain glutathione analogs |
| NZ255541A (en) | 1992-09-09 | 1996-05-28 | Fisons Plc | Blister package for medicament-containing capsules with an aperture for dispensing the medicament; the package base has a sealing means to seal the capsule aperture |
| US5571783A (en) | 1993-03-09 | 1996-11-05 | Clintec Nutrition Company | Composition and method for treating patients with hepatic disease |
| JP3273578B2 (ja) | 1993-09-21 | 2002-04-08 | 第一化学薬品株式会社 | オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法 |
| US6083953A (en) | 1994-07-28 | 2000-07-04 | Syntex (U.S.A.) Inc. | 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative |
| IL116674A (en) | 1995-01-09 | 2003-05-29 | Mendell Co Inc Edward | Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof |
| AU2251897A (en) | 1996-02-13 | 1997-09-02 | Trustees Of The University Of Pennsylvania, The | Method of treating liver disorders |
| ZA986614B (en) | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
| GB9815567D0 (en) | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| US6258849B1 (en) | 1998-07-23 | 2001-07-10 | Stanislaw R. Burzynski | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
| EP1179347A4 (en) | 1999-05-21 | 2002-06-26 | Takeda Chemical Industries Ltd | CONTROL SUBSTANCES FOR LIVER FUNCTION |
| US6768024B1 (en) | 2000-08-04 | 2004-07-27 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
| JP3211824B1 (ja) | 2000-10-26 | 2001-09-25 | 味の素株式会社 | 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法 |
| EP1374863B1 (en) | 2001-03-15 | 2009-09-02 | Riken | Amino acid compositions for ameliorating liver failure |
| US6503530B1 (en) | 2001-11-01 | 2003-01-07 | Chunghee Kimberly Kang | Method of preventing development of severe metabolic derangement in inborn errors of metabolism |
| US20030105104A1 (en) | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| CN1383815A (zh) | 2002-05-08 | 2002-12-11 | 刘万忠 | 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法 |
| US20040152784A1 (en) | 2002-07-23 | 2004-08-05 | Special Products Limited | Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia |
| JPWO2004019928A1 (ja) | 2002-08-30 | 2005-12-15 | 味の素株式会社 | 肝疾患治療剤 |
| US20050059150A1 (en) * | 2003-09-17 | 2005-03-17 | Becton, Dickinson And Company | Environments that maintain function of primary liver cells |
| MXPA03009902A (es) * | 2003-10-29 | 2005-05-03 | Manuel Francisco Lara Och Jose | Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio. |
| JP5064037B2 (ja) * | 2004-02-23 | 2012-10-31 | ジェネンテック， インコーポレイテッド | 複素環式自壊的リンカーおよび結合体 |
| AU2005240257B2 (en) * | 2004-05-06 | 2011-11-24 | Osteologix A/S | High yield and rapid syntheses methods for producing metallo-organic salts |
| US20060045912A1 (en) | 2004-08-30 | 2006-03-02 | Peter Truog | 4-phenylbutyric acid controlled-release formulations for therapeutic use |
| GB0426141D0 (en) * | 2004-11-26 | 2004-12-29 | Ucl Biomedica Plc | Treatment |
| WO2006056794A1 (en) | 2004-11-26 | 2006-06-01 | Ucl Business Plc | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
| PL1948224T3 (pl) | 2005-11-17 | 2014-10-31 | Silverstone Pharma Est | Trwały preparat amorficznych soli peryndoprylu, sposób ich wytwarzania, zwłaszcza wytwarzania w skali przemysłowej oraz ich zastosowanie w terapii nadciśnienia |
| AU2015221466B2 (en) | 2009-04-03 | 2017-02-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| SMT201700601T1 (it) | 2009-04-03 | 2018-03-08 | Ocera Therapeutics Inc | L-ornitina fenilacetato e metodi per la sua fabbricazione |
| CA2763894A1 (en) | 2009-06-02 | 2011-01-13 | Salix Pharmaceuticals, Ltd. | Use of rifaximin to maintain remission of hepatic encephalopathy |
| AU2014250643B2 (en) | 2009-06-08 | 2016-07-14 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
| EP2799067B1 (en) | 2009-06-08 | 2019-04-03 | UCL Business PLC | Treatment of brain inflammation using L-Ornithine Phenylacetate |
| JP2011236160A (ja) | 2010-05-11 | 2011-11-24 | Shinshu Univ | 非アルコール性肝疾患治療薬 |
| NZ609191A (en) | 2010-10-06 | 2015-06-26 | Ocera Therapeutics Inc | Methods of making l-ornithine phenyl acetate |
| LT2922576T (lt) | 2012-11-21 | 2018-02-12 | Horizon Therapeutics, Llc | Azotą surišančių vaistų, skirtų kepenų encefalopatijos gydymui, skyrimo ir įvertinimo būdai |
| KR20230018526A (ko) | 2014-11-24 | 2023-02-07 | 유씨엘 비즈니스 리미티드 | 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료 |
| KR20180006904A (ko) | 2015-04-20 | 2018-01-19 | 오세라 테라퓨틱스, 아이엔씨. | L-오르니틴 페닐아세테이트의 제형 |
| HK1249434A1 (zh) | 2015-08-18 | 2018-11-02 | Ocera Therapeutics, Inc. | 使用与苯乙酸盐和苯丁酸盐中的至少一种组合的l-鸟氨酸治疗和预防肌肉损失 |
-
2010
- 2010-04-01 SM SM20170601T patent/SMT201700601T1/it unknown
- 2010-04-01 NZ NZ619235A patent/NZ619235A/en unknown
- 2010-04-01 ES ES20161306T patent/ES2928586T3/es active Active
- 2010-04-01 DK DK10759442.6T patent/DK2413924T3/en active
- 2010-04-01 CA CA2757373A patent/CA2757373C/en active Active
- 2010-04-01 MX MX2011010262A patent/MX2011010262A/es active IP Right Grant
- 2010-04-01 KR KR1020207016586A patent/KR102217081B1/ko not_active Expired - Fee Related
- 2010-04-01 MX MX2018006692A patent/MX375111B/es unknown
- 2010-04-01 EP EP20161306.4A patent/EP3686183B1/en active Active
- 2010-04-01 HU HUE20161306A patent/HUE060371T2/hu unknown
- 2010-04-01 EA EA201171216A patent/EA023051B1/ru not_active IP Right Cessation
- 2010-04-01 CA CA2998344A patent/CA2998344C/en active Active
- 2010-04-01 KR KR1020187008530A patent/KR101975726B1/ko active Active
- 2010-04-01 EP EP22185562.0A patent/EP4101838A1/en active Pending
- 2010-04-01 KR KR1020217004211A patent/KR102399540B1/ko active Active
- 2010-04-01 EP EP10759442.6A patent/EP2413924B1/en active Active
- 2010-04-01 KR KR1020117026256A patent/KR101844605B1/ko active Active
- 2010-04-01 PL PL10759442T patent/PL2413924T3/pl unknown
- 2010-04-01 HR HRP20221232TT patent/HRP20221232T8/hr unknown
- 2010-04-01 PT PT201613064T patent/PT3686183T/pt unknown
- 2010-04-01 EP EP17185173.6A patent/EP3263100B1/en active Active
- 2010-04-01 EA EA201500650A patent/EA034409B1/ru not_active IP Right Cessation
- 2010-04-01 SG SG10202010988WA patent/SG10202010988WA/en unknown
- 2010-04-01 CN CN201410392027.XA patent/CN104230730B/zh active Active
- 2010-04-01 NO NO10759442A patent/NO2413924T3/no unknown
- 2010-04-01 CN CN201080021311.6A patent/CN102421432B/zh active Active
- 2010-04-01 MX MX2020009699A patent/MX388894B/es unknown
- 2010-04-01 KR KR1020227016294A patent/KR20220067001A/ko not_active Abandoned
- 2010-04-01 CA CA2998434A patent/CA2998434C/en active Active
- 2010-04-01 DK DK17185173.6T patent/DK3263100T3/da active
- 2010-04-01 CN CN201710053850.1A patent/CN106810464B/zh active Active
- 2010-04-01 NZ NZ595706A patent/NZ595706A/en unknown
- 2010-04-01 JP JP2012503725A patent/JP6144488B2/ja active Active
- 2010-04-01 CA CA3205755A patent/CA3205755A1/en active Pending
- 2010-04-01 SG SG10201406300YA patent/SG10201406300YA/en unknown
- 2010-04-01 WO PCT/US2010/029708 patent/WO2010115055A1/en not_active Ceased
- 2010-04-01 HR HRP20171962TT patent/HRP20171962T1/hr unknown
- 2010-04-01 AU AU2010232521A patent/AU2010232521B2/en active Active
- 2010-04-01 BR BRPI1013657A patent/BRPI1013657A2/pt not_active Application Discontinuation
- 2010-04-01 CA CA3077846A patent/CA3077846C/en active Active
- 2010-04-01 MX MX2014008993A patent/MX356608B/es unknown
- 2010-04-01 ES ES10759442.6T patent/ES2652187T3/es active Active
- 2010-04-01 SM SM20220395T patent/SMT202200395T1/it unknown
- 2010-04-01 LT LTEP10759442.6T patent/LT2413924T/lt unknown
- 2010-04-01 ES ES17185173T patent/ES2791524T3/es active Active
- 2010-04-01 SG SG2011071164A patent/SG174982A1/en unknown
- 2010-04-01 HU HUE10759442A patent/HUE035921T2/en unknown
- 2010-04-01 KR KR1020197012203A patent/KR102123243B1/ko active Active
- 2010-04-01 SI SI201031596T patent/SI2413924T1/en unknown
- 2010-04-01 NZ NZ708458A patent/NZ708458A/en unknown
- 2010-04-01 PT PT107594426T patent/PT2413924T/pt unknown
- 2010-04-01 LT LTEP20161306.4T patent/LT3686183T/lt unknown
- 2010-04-01 PL PL20161306.4T patent/PL3686183T3/pl unknown
- 2010-04-01 DK DK20161306.4T patent/DK3686183T3/da active
- 2010-04-02 US US12/753,763 patent/US8173706B2/en not_active Expired - Fee Related
-
2011
- 2011-09-30 ZA ZA2011/07189A patent/ZA201107189B/en unknown
- 2011-10-02 IL IL215449A patent/IL215449B/en active IP Right Grant
-
2012
- 2012-03-30 US US13/436,642 patent/US8492439B2/en active Active
-
2013
- 2013-07-08 US US13/937,107 patent/US8785498B2/en active Active
-
2014
- 2014-06-09 US US14/299,940 patent/US9034925B2/en active Active
-
2015
- 2015-02-20 JP JP2015031199A patent/JP6010154B2/ja active Active
- 2015-05-18 US US14/715,481 patent/US9604909B2/en active Active
-
2016
- 2016-12-07 JP JP2016237164A patent/JP6328737B2/ja active Active
-
2017
- 2017-03-24 US US15/469,359 patent/US10173964B2/en active Active
- 2017-12-20 CY CY20171101334T patent/CY1119843T1/el unknown
-
2018
- 2018-04-18 JP JP2018079490A patent/JP6647336B2/ja not_active Expired - Fee Related
- 2018-07-17 US US16/037,655 patent/US10550069B2/en active Active
- 2018-12-18 IL IL263784A patent/IL263784A/en unknown
-
2020
- 2020-01-14 JP JP2020003346A patent/JP7086118B2/ja active Active
- 2020-01-31 US US16/778,696 patent/US11161802B2/en active Active
-
2021
- 2021-11-01 US US17/516,591 patent/US20220162155A1/en active Pending
-
2022
- 2022-03-25 JP JP2022049427A patent/JP2022088504A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2791524T3 (es) | Fenilacetato de L-ornitina y métodos de elaboración del mismo | |
| ES2720148T3 (es) | Métodos de fabricación de fenilacetato de L-ornitina | |
| AU2017202081B2 (en) | L-ornithine phenyl acetate and methods of making thereof | |
| HK40033714B (en) | L-ornithine phenyl acetate and methods of making thereof | |
| HK40033714A (en) | L-ornithine phenyl acetate and methods of making thereof | |
| HK1248558B (en) | L-ornithine phenyl acetate and methods of making thereof | |
| HK1166699A (en) | L-ornithine phenyl acetate and methods of making thereof | |
| HK1166699B (en) | L-ornithine phenyl acetate and methods of making thereof |